Teva Pharmaceutical Industries Ltd ADR has reached a significant milestone as its stock hit a 52-week high, trading at $25.96. This achievement marks a notable recovery and growth trajectory for the ...

What Happened: A Form 4 filing with the U.S. Securities and Exchange Commission on Monday outlined that Weiss executed a sale ...

In its third quarter, Teva booked revenue of $4.48 billion. That was 3% higher year over year, and much of that growth came ...

Israel-based Phoenix Financial acquired more than 3.5 million additional shares of Teva Pharmaceuticals for an estimated $62.1 million in the third quarter. Post-transaction, the fund reported holding ...

The Israeli pharmaceutical company, managed by CEO Richard Francis, will publish its third quarter financial results on ...

Teva CEO Richard Francis said, "Following the conclusion of the IRA pricing negotiations, we are reiterating our strong ...

Teva Pharmaceutical Indus (NYSE: TEVA) has outperformed the market over the past 5 years by 6.92% on an annualized basis producing an average annual return of 20.65%. Currently, Teva Pharmaceutical ...

Teva Pharmaceutical Industries Ltd ADR stock has reached a new 52-week high, touching 23.07 USD. This milestone reflects a significant upward trend in the company’s stock performance over the past ...

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest ...

Teva shares jumped 12% after Q3 earnings beat estimates, driven by strong branded drug sales led by Austedo and solid guidance for 2025.